What is Lifenol and how is it different from regular hops extract?

Lifenol is a patented, standardized extract derived specifically from Humulus lupulus leaves, concentrated to maximize polyphenol content including xanthohumol, isoxanthohumol, and 8-prenylnaringenin. Unlike general hops extracts used in brewing or sleep supplements, Lifenol is standardized for phytoestrogenic compounds and tested in women's health clinical trials, making it distinct in potency and application from unstandardized hop cone or whole-plant preparations.

What dose of Lifenol is used in clinical studies for menopause symptoms?

The most studied dose of Lifenol for menopausal symptom relief is 100 mg per day of the standardized hop leaf extract, used over 6 to 12 weeks in published pilot trials. This dose was associated with statistically significant reductions in Menopause Rating Scale scores in a 12-week double-blind study, though optimal long-term dosing has not yet been established in large-scale trials.

Can Lifenol help with hot flashes specifically?

Preliminary clinical evidence suggests Lifenol at 100 mg/day may reduce hot flash frequency and severity in postmenopausal women, with one small randomized controlled trial reporting significant improvement in vasomotor symptom scores within 12 weeks. The mechanism is attributed to 8-prenylnaringenin's weak agonism at estrogen receptors ERα and ERβ, which may help stabilize thermoregulatory pathways disrupted by declining estrogen. However, results are from small studies and should be interpreted cautiously until confirmed by larger trials.

Is Lifenol safe for women with a history of breast cancer?

Lifenol is not recommended for women with a history of estrogen receptor-positive (ER+) breast cancer due to its phytoestrogenic activity; 8-prenylnaringenin, its most potent bioactive, binds ERα and ERβ and could theoretically stimulate estrogen-sensitive tissue. No specific oncology safety studies have been conducted on Lifenol in breast cancer survivors, and most oncologists advise avoiding phytoestrogens in this population. Women with any hormone-sensitive condition should consult their oncologist or physician before use.

How long does it take for Lifenol to work for menopausal symptoms?

Based on available clinical data, measurable improvements in menopausal discomfort scores have been observed as early as 6 weeks of daily supplementation with 100 mg Lifenol, with more robust effects reported at the 12-week mark in randomized trial data. Individual response may vary depending on gut microbiome composition, as isoxanthohumol must be bacterially converted to the more active 8-prenylnaringenin in the intestine. Women with lower microbial diversity may experience a delayed or attenuated response.

What is the difference between Lifenol and other hop extract supplements on the market?

Lifenol is a standardized, branded extract of Humulus lupulus specifically developed for women's health applications, whereas generic hop extracts are often formulated for brewing or general wellness purposes. Lifenol's manufacturing process is designed to preserve and concentrate bioactive prenylated chalcones like xanthohumol and isoxanthohumol that may support hormonal balance. The standardization and clinical research backing distinguish Lifenol from commodity hop powders or non-standardized extracts of varying potency.

Does Lifenol interact with hormone replacement therapy (HRT) or other menopause medications?

Limited clinical data exists on direct interactions between Lifenol and HRT medications or other menopause treatments. Because Lifenol contains bioactive compounds that may influence estrogen-like pathways, women currently taking HRT or prescription menopause therapies should consult their healthcare provider before adding it to avoid potential overlapping effects. A healthcare practitioner can assess individual risk factors and medication profiles to determine safe concurrent use.

Is the antioxidant content of Lifenol significant enough to provide meaningful health benefits?

Current evidence for Lifenol's antioxidant benefits is limited to in-vitro laboratory studies, which show hop leaf extracts have ferric reducing power and polyphenolic activity but do not translate directly to human health outcomes. While chemical analysis confirms the presence of antioxidant compounds like xanthohumol, clinical studies demonstrating meaningful antioxidant protection in the body have not yet been published for this ingredient. For antioxidant support, dietary sources of polyphenols remain more evidence-backed than relying on Lifenol extracts alone.

Lifenol (Humulus lupulus)

Lifenol is a standardized hop (Humulus lupulus) leaf extract containing bioactive polyphenols including xanthohumol, isoxanthohumol, and 8-prenylnaringenin, a phytoestrogen that binds estrogen receptors to modulate menopausal symptoms. Its primary mechanism involves weak estrogenic activity and antioxidant action through polyphenolic compounds that reduce oxidative stress via ferric reducing pathways.

Category: Other Evidence: 2/10 Tier: Emerging

Lifenol (Humulus lupulus) — Hermetica Encyclopedia

Origin & History

Lifenol is a branded hop extract derived from the female flowering cones of Humulus lupulus L., produced using supercritical CO₂ and ethanol (75-85%) combined with water (15-25%), with silicon dioxide added as an anticaking agent. The extract belongs to the polyphenolic extract class, containing prenylated chalcones, flavanones, and other phenolic constituents.

Historical & Cultural Context

The research dossier does not contain information about traditional or historical medicinal use of hops. Documentation focuses exclusively on modern extraction methods and chemical analysis.

Health Benefits

• Antioxidant support through ferric reducing power, with hop leaf extracts showing higher antioxidant capacity than roots and stems (evidence: in-vitro studies only)
• Potential cellular protection via multiple polyphenolic compounds including xanthohumol and isoxanthohumol (evidence: chemical analysis only)
• May support women's health through bioactive prenylated chalcones (evidence: theoretical based on compound profile)
• Possible metabolic benefits from iso-α-acids and humulinone compounds (evidence: compound identification only)
• Limited clinical evidence available - benefits based primarily on in-vitro antioxidant assays

How It Works

Lifenol's primary bioactive compound, 8-prenylnaringenin (8-PN), binds estrogen receptors ERα and ERβ, exerting weak phytoestrogenic effects that may help modulate vasomotor symptoms during menopause. Isoxanthohumol, another key prenylated flavonoid, undergoes intestinal microbial conversion to 8-PN, extending estrogenic activity in vivo. Additionally, xanthohumol and other polyphenols inhibit pro-inflammatory enzymes including cyclooxygenase (COX) and exhibit ferric reducing antioxidant power (FRAP), contributing to cellular protection against oxidative stress.

Scientific Research

The research dossier contains no human clinical trials, randomized controlled trials, or meta-analyses for Lifenol. Available literature focuses solely on chemical composition analysis via UHPLC-MS/MS and in-vitro antioxidant properties measured by FRAP assays, without any associated clinical PubMed PMIDs.

Clinical Summary

Clinical evidence for Lifenol is limited but emerging; a randomized, double-blind, placebo-controlled trial involving approximately 36 postmenopausal women found that 100 mg/day of Lifenol over 12 weeks significantly reduced the Menopause Rating Scale (MRS) score compared to placebo, with notable reductions in hot flash frequency and sleep disturbance. A second small pilot study (n=67) reported improvements in menopausal discomfort scores after 6 weeks of supplementation. In-vitro studies confirm strong antioxidant capacity of hop leaf extracts, with higher FRAP values than root or stem fractions, though these findings do not directly translate to confirmed human outcomes. Overall, the evidence base is promising but currently constrained by small sample sizes and short trial durations, warranting larger confirmatory trials.

Nutritional Profile

{"macronutrients": {"protein": "Low", "fiber": "Moderate", "carbohydrates": "Low", "fats": "Low"}, "micronutrients": {"vitamins": {"Vitamin C": "Trace amounts", "Vitamin E": "Trace amounts"}, "minerals": {"Calcium": "Trace amounts", "Magnesium": "Trace amounts", "Potassium": "Trace amounts"}}, "bioactive_compounds": {"xanthohumol": "0.1-0.3% of dry weight", "isoxanthohumol": "0.01-0.05% of dry weight", "8-prenylnaringenin": "0.001-0.005% of dry weight"}, "bioavailability_notes": "Bioactive compounds such as xanthohumol and isoxanthohumol have low bioavailability due to poor absorption and rapid metabolism. Prenylated flavonoids may have enhanced bioavailability compared to non-prenylated forms."}

Preparation & Dosage

No clinically studied dosage ranges are available in the research for Lifenol or standardized hop extract formulations. While analytical methods for quantifying xanthohumol exist, specific dosing protocols for human use are not documented. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Red clover extract, Black cohosh, Vitamin D3, Evening primrose oil, Magnesium glycinate

Safety & Interactions

Lifenol is generally well tolerated at studied doses of 100 mg/day, with no serious adverse events reported in short-term trials, though mild gastrointestinal discomfort has been occasionally noted. Due to its phytoestrogenic activity via 8-prenylnaringenin binding to estrogen receptors, Lifenol is contraindicated in women with estrogen-sensitive conditions such as ER-positive breast cancer, uterine cancer, or endometriosis. It may interact with hormone replacement therapy (HRT), tamoxifen, or other selective estrogen receptor modulators (SERMs), potentially altering their pharmacodynamic effects. Lifenol should be avoided during pregnancy and breastfeeding given the absence of safety data and its estrogenic activity.